Table 1.
Overview of the ongoing clinical trials of nucleic acid vaccines against COVID-19 (assess at ClinicalTrials.gov as of November 02, 2020).
| Study start date/study identifier | Technology | Study phase/ECD | Project title | Immunogen | Via | Subjects | Number of subjects | Study location |
|---|---|---|---|---|---|---|---|---|
| June 17, 2020/NCT04445389 | DNA vaccine | Phase 1–2 June 2022 |
Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults | S protein | IM | Adults (18–50 years old) | 210 | Korea |
| July 29, 2020/NCT04463472 | DNA vaccine | Phase 1–2 July 2021 |
Study of COVID-19 DNA Vaccine (AG0301-COVID19) | S protein | IM | Adults (20–65 years old) | 30 | Japan |
| August 31, 2020/NCT04527081 | DNA vaccine | Phase 1–2 September 2021 |
Study of COVID-19 DNA Vaccine (AG0302-COVID19) | S protein | IM | Adults (20–65 years old) | 30 | Japan |
| April 3, 2020/NCT04336410 | DNA vaccine | Phase 1 July 2021 |
Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers | S protein | ID (EP) | Adults (18 years and older) | 120 | United States |
| July 2020/NCT04334980 | DNA vaccinea | Phase 1/ February 2022 |
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 | S protein | oral | Adults (18 years and older) | 12 | Australia |
| November 2020/NCT04591184 | DNA vaccine | Phase 1 June 2021 |
A Clinical Trial of a Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults | S protein | IM | Adults (18 to 84 years old) | 72 | Canada |
| March 16, 2020/NCT04470427 | mRNA vaccineb | Phase 3 October 2022 |
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19) | S protein | IM | Adults (18 years to 99 Years old) | 30,000 | United States |
| June 18, 2020/NCT04515147 | mRNA vaccine | Phase 2 November 2021 |
A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults | S protein | IM | Adults (18–60 years old) | 691 | Germany |
| April 23, 2020/NCT04368728 | mRNA Vaccineb | Phase 2–3 December 2022 |
A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults | S protein | IM | Adults (18–85 years old) | 29,481 | Germany |
| January 2021/NCT04566276 | mRNA vaccineb | Phase 1 June 2021 |
ChulaCov19 mRNA Vaccine in Healthy Adults | S protein | IM | Adults (18–75 years old) | 96 | Thailand |
ECD, Estimated Study Completion Date; IM, intramuscular; EP, electroporation; ID, intradermal.
a
Bifidiobacterium longum.
b
Lipid nanoparticle-encapsulated mRNA.